Top 3 Notable Winners: EVLTL, DBVT, BVXV
3:55 pm Wednesday, December 22nd, 2021
Vertical Aerospace (NYSE:EVTL), the British flying taxi company that went public through a de-spacing deal last week, rose 14% as the company rang the opening bell at the NYSE this morning and amid social media mentions. Vertical Aerospace started trading last week after holders of SPAC Broadstone Acquisition approved a deal with Vertical Aerospace (EVTL). The company earlier tweeted that it would be ringing the opening bell at the iconic NYSE. Vertical is the fourth electric vertical takeoff and landing aircraft company to go public this year. Vertical says it has received conditional pre-orders for a total of up to 1,350 aircraft from American Airlines, Avolon, Bristow and Iberojet, which includes conditional pre-order options from Virgin Atlantic and Marubeni.
Shares of DBV Technologies (NASDAQ:DBVT) have recouped some of their losses from yesterday after the company announced a new late-stage trial for its Viaskin peanut allergy patch. The trial will evaluate a modified patch that is 50% larger than a previous version. Kempen analyst Alex Cogut today downgraded DBV to neutral from buy with a $1.10 price target (~21% downside based on yesterday’s close).
Nano-cap stock, BiondVax Pharmaceuticals (NASDAQ:BVXV) has more than doubled in the pre-market on above-average volume after announcing the signing of definitive agreements with two German institutes for the development and commercialization of COVID-19 nanosized antibodies. The agreements with Max Planck Society (MPG) and the University Medical Center Göttingen (UMG) are part of a broader partnership expected to be signed in Jan. 2022, the company announced.
The lead NanoAb COVID-19 candidates in the program have a robust competitive advantage over the current treatments for the disease, BiondVax (BVXV) argues. The company cites their ability to bind the target at concentrations 100-times lower than those required by commercially available monoclonal antibody treatments for COVID-19.
